12:00 AM
 | 
Feb 26, 2007
 |  BioCentury  |  Strategy

Development deficit

Development deficit

Development deficit
Given the number of marketed ADHD drugs, the dearth of new compounds in the clinic is not surprising. Aside from the two Shire compounds awaiting approval, the next one up would have been Sparlon modafinil from Cephalon. But CEPH discontinued development after receiving an FDA not approvable letter for the indication last year. (A) Generic guanfacine...

Read the full 304 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >